癌症研究
PARP抑制剂
医学
卵巢癌
体内
腹水
免疫系统
恶性胸腔积液
肿瘤微环境
联合疗法
胸腔积液
下调和上调
体外
免疫疗法
浆液性液体
癌症
炎症
聚ADP核糖聚合酶
DNA损伤
促炎细胞因子
癌细胞
先天免疫系统
DNA修复
靶向治疗
肿瘤坏死因子α
血管生成
作者
Yan Fang,Qian Shen,Yi Lin,Jing Zhu,Xiaolan Zhu,Rui Huang,Yue Wu,Feiyang Shen,Qian Li,Guopei Zheng,Zhe Zhang,Qian Chu,Junhao Hu,Jianfeng Shen
标识
DOI:10.1002/advs.202510547
摘要
Malignant serous effusion (MSE), including malignant pleural effusion (MPE) and malignant ascites (MA), is a common and severe complication in advanced malignancies, associated with poor prognosis and high recurrence rates. Currently, no standardized treatments are available for MSE management, posing significant clinical challenges. Here, we identify elevated LIN28B expression and dysregulation of DNA repair pathways as two major features associated with MSE from patient and preclinical samples. We develop a targeted siRNA nanoparticle delivery system (siLin28B/DSSP@lip-PEG-FA) in combination with the PARP inhibitor BMN673, providing a synergistic therapeutic strategy against MSE. This combination significantly alleviated MA accumulation and prolonged survival in a preclinical ovarian cancer (OC) model without causing systemic cytotoxicity. Mechanistically, single-cell RNA sequencing (scRNA-seq) revealed that this combination therapy markedly remodeled the immune microenvironment by decreasing M2 macrophages and neutrophil populations with altered subtypes. Notably, Arg1-positive neutrophils, producing pro-inflammatory cytokines to increase vascular permeability, were diminished after the combination treatment. Furthermore, in vitro and in vivo experiments demonstrated that suppression of PARP and LIN28B inhibited vascular leakage and reinforced tight junction integrity. Collectively, our findings highlight dual targeting of PARP and LIN28B as a promising MA management approach in patients with advanced cancers, with the potential to improve patient quality of life.
科研通智能强力驱动
Strongly Powered by AbleSci AI